MedTrace Logo

AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)

NCT02595255 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 275

Last updated 2020-05-04

No results posted yet for this study

Summary

While most of the children spontaneously recover menstruation or experienced normal puberty after chemotherapy, their ovarian reserve may be impaired by treatment inducing future infertility. Fertility preservation is currently proposed for selected prepubertal patients with a high risk of premature ovarian failure after treatment (mostly conditioning regimen for bone marrow transplantation). For patients with low or moderate risks, counselling is very difficult and no fertility preservation procedure is usually proposed for these patients as no marker of the ovarian reserve has been validated in this young population to assess the individual risk.

The primary objective of the study is to prevent long-term treatment-related infertility by detecting the young patients who normally progressed to menarche but have a reduced ovarian reserve. These patients may benefit from particular follow-up and fertility preservation procedure.

Conditions

  • Fertility Preservation
  • Lymphoma
  • Pediatrics Cancer
  • Gonadotropin-releasing Hormone Agonist

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Queen Fabiola Children's University Hospital

    collaborator OTHER

  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Isabelle Demeestere, PhD · Erasme ULB- Belgium

  • Alina Ferster · Queen Fabiola children's university hospital- Belgium

  • Christine Decanter · CHRU Lille, France

Eligibility

Min Age
3 Years
Max Age
14 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2021-12-31
Completion
2036-12-31

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02595255 on ClinicalTrials.gov